中国医学前沿杂志（电子版）Issue(6)：147-149,3.
伊立替康联合长春瑞滨二线治疗晚期食管癌的疗效分析
Irinotecan and vinorelbine as second-line therapy for advanced esophageal carcinoma
覃莉 1黄东宁 1黄健 1郑志勇1
作者信息
- 1. 柳州市工人医院 肿瘤科，广西 柳州545005
- 折叠
摘要
Abstract
ObjectiveTo deifne the efifcacy of irinotecan combined with vinorelbine as second-line therapy of patients with advanced esophageal carcinoma.MethodEvaluated 31 patients treated with irinotecan combined with vinorelbine from January 2012 to January 2014, patients who had received platinum-based or paclitaxel-based treatment had been documented progressive disease. Irinotecan combined with vinorelbine were administered to each patient, irinotecan 50 mg/m2 and vinorelbine 25 mg/m2 on day 1 and day 8 every 3 weeks.Result31 patients were assessable for response. No patient got complete response (CR). 7 cases (22.6%) were partial responses (PR), 10 cases (32.3%) were stable diseases (SD) and 14 cases (45.2%) were progressive diseases (PD). The overall response rate was 22.6% (7/31), the disease control rate was 54.8% (17/31). The median progression-free survival (PFS) was 13 weeks (95%CI: 9~15 weeks) and the median overall survival (OS) was 23 weeks (95%CI: 12~34 weeks). No serious adverse reactions were identiifed. ConclusionIrinotecan combined with vinorelbine is a safe and effective second-line therapy for advanced esophageal carcinoma.关键词
晚期食管癌/伊立替康/长春瑞滨/二线治疗Key words
Advanced esophageal carcinoma/Irinotecan/Vinorelbine/Second-line chemotherapy引用本文复制引用
覃莉,黄东宁,黄健,郑志勇..伊立替康联合长春瑞滨二线治疗晚期食管癌的疗效分析[J].中国医学前沿杂志（电子版）,2015,(6):147-149,3.
